Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ChIP-seq profiles of primary, metastatic, drug-resistant and drug-holiday cells

ABSTRACT: ChIP-seq profiles of primary, metastatic, drug-resistant and drug-holiday cells

PROVIDER: PRJNA493811 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR7941340.fastq.gz	Fastqsanger.gz
	SRR7941341.fastq.gz	Fastqsanger.gz
	SRR7941332.fastq.gz	Fastqsanger.gz
	SRR7941342.fastq.gz	Fastqsanger.gz
	SRR7941333.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 17

Similar Datasets

Single cell RNA-seq profiles of primary, metastatic, drug-resistant and drug-holiday cells

Project description:Single cell RNA-seq profiles of primary, metastatic, drug-resistant and drug-holiday cells

| PRJNA483471 | ENA

Single cell RNA-seq profiles of primary, metastatic, drug-resistant and drug-holiday cells

Project description:We employed Single cell RNA-seq to identify the transcriptome of cisplatin sensitive, resistant and drug-holiday cells from patient-derived OSCC cells isolated from primary and metastatic sites.

2018-11-22 | GSE117872 | GEO

ChIP-seq profiles of primary, metastatic, drug-resistant and drug-holiday cells

Project description:We employed ChIP-seq to detect poised and active chromatin regions in cisplatin sensitive and resistant head neck squamous cell carcinoma patient derived primary and lymph node cell lines.

2018-11-22 | GSE120634 | GEO

miRNA sequence analysis of drug-resistant small cell lung cancer

Project description:We obtained small cell lung cancer specimens and normal lung specimens from patients who died of drug-resistant SCLC. The small lung cancer specimens include primary lesions and metastatic lesions. Next generation sequencing was performed to assess the expression of miRNA in drug-resistant small cell lung cancer.

2021-06-05 | GSE176198 | GEO

Transcription profiling of human TRAIL-resistant metastatic vs primary TRAIL-sensitive melanoma cells

Project description:T1 and G1 are the two melanoma cell lines, established from primary tumor (T1) and lymph node metastases (G1) of a 77 years old male patient. While G1 cells were resistant to TRAIL (TNF-related apoptosis-inducing ligand) mediated cell death, T1 cells exhibited a high dose- and time-dependent sensitivity to TRAIL. Cells were treated with or without of two doses (0.2 and 1ug/ml) of TRAIL for 24 h. Gene expression of each sample vs pool was measured. TRAIL-resistant metastatic G1 vs primary TRAIL-sensitive T1 was compared.

2006-01-01 | E-MEXP-247 | biostudies-arrayexpress

RNA expression profiles of drug-resistant TNBC cell lines after chemotherapy

Project description:RNA expression profiles of drug-resistant TNBC cell lines after chemotherapy

| PRJNA958171 | ENA

Expression Profiles of miRNAs in Drug-Resistant Non-small Cell Lung Cancer Cell Lines Using Next Generation Sequencing

Project description:The expression profiles of miRNAs in drug-resistant non-small cell lung cancer (NSCLC) cell lines were identified via next generation sequencing and the common dysregulated miRNAs in drug-resistant NSCLC cell lines were picked up for further analysis.

2020-11-01 | GSE122452 | GEO

Expression data of BRAF inhibitor resistant melanoma cells

Project description:We generated four drug-resistant melanoma cell lines from paired primary/metastatic cell lines using PLX4720 and used for Affymetrix Human Gene 1.0 ST array

2019-01-31 | GSE114443 | GEO

Drug-resistant acute myeloid leukemia

Project description:Drug-resistant acute myeloid leukemia

| PRJNA828404 | ENA

Whole Genome Methylation Analysis of Metastatic Castration Resistant Prostate Cancer

Project description:Relatively little is known about how changes in gene copy number (CN) and gene CpG methylation interact to affect specific pathways in metastatic castration-resistant prostate cancer (CRPC). Oligonucleotide array comparative genomic hybridization (aCGH) was performed on DNA isolated from 15 metastatic CRPC samples. Commonly aberrant genes were evaluated in a confirmatory fashion using PCR, aCGH data from primary tumors, and existing CRPC expression data. Array-based comprehensive CpG methylation was assessed on the same sample set. A total of 495 genes (79 gained, 416 deleted) were CN aberrant in ?66% of the samples by aCGH, and 77 (9 amplified, 68 deleted) had statistically concordant expression including gain of AR and loss of PTEN and RB1. Significant CN differences were seen between the genomes of patients with AR-amplified and AR-unamplified tumors, including common loss of AR repressors in AR-unamplified tumors. The majority of CRPC samples were hypermethylated compared to benign prostate tissue. Simultaneous methylation and heterozygous gene deletion occurred in the tumor suppressor RB1 and in HSD17B2, responsible for testosterone metabolism. Establishment of a comprehensive methylation signature and coupling of epigenomic and structural analyses sheds light on the alterations that allow CRPC to circumvent hormonal therapy and may provide new drug targets for what is currently an incurable disease state. 15 tumor samples taken from 14 men with metastatic castration resistant prostate cancer were analyzed, including two samples from the same patient. No control samples were used for this experiment.

2011-12-06 | E-GEOD-34174 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data